Role of GLP-1 agonists in managing comorbidities in HFpEF Beyond their cardioprotective properties, GLP-1 receptor agonists exert a beneficial impact on HFpEF by influencing other organ systems and mitigating comorbid conditions that contribute to its progression, including metabolic dysfunction-associated steatotic liver disease (MASLD), chronic kidney disease, and pulmonary disorders
TMA is a precursor to TMAO, and its dietary precursors are generally choline, L-carnitine, and betaine ( Table 1
Of note, albiglutide (TANZEUM) and tirzepatide (MOUNJARO) were not included in our study, given that albiglutide has been discontinued in the United States market since 26 July 2017, and tirzepatide was approved by the FDA in May 2022
Untreated hearing loss can increase cognitive load, reduce social engagement, and change how the brain processes the environment
Chirag Patel & Chintu Patel Co-Founders & Co-CEOs, Amneal Pharmaceuticals In 2025, the rules of pharma growth changed